ORAMED PHARMACEUTICALS: Leadership/Comp Changes Reported in 8-K
Ticker: ORMP · Form: 8-K · Filed: Jan 19, 2024 · CIK: 1176309
| Field | Detail |
|---|---|
| Company | Oramed Pharmaceuticals Inc. (ORMP) |
| Form Type | 8-K |
| Filed Date | Jan 19, 2024 |
| Risk Level | medium |
| Pages | 1 |
| Reading Time | 2 min |
| Key Dollar Amounts | $0.012 |
| Sentiment | neutral |
Complexity: simple
Sentiment: neutral
Topics: executive-changes, compensation, corporate-governance
TL;DR
**Oramed filed an 8-K about leadership/compensation changes, watch for details.**
AI Summary
Oramed Pharmaceuticals Inc. filed an 8-K on January 19, 2024, reporting an event that occurred on January 17, 2024, related to "Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers." This filing indicates changes in leadership or executive compensation, which could signal strategic shifts or financial adjustments within the company. For investors, understanding these changes is crucial as they can impact future company performance and stock valuation.
Why It Matters
Changes in executive leadership or compensation can signal strategic shifts or financial adjustments, directly impacting investor confidence and the company's future direction.
Risk Assessment
Risk Level: medium — The filing indicates changes in leadership or compensation, which can introduce uncertainty or signal strategic shifts that may carry both opportunities and risks.
Analyst Insight
Investors should monitor subsequent filings or company announcements for specific details regarding the reported changes in leadership or compensation, as these will provide clarity on the impact to Oramed Pharmaceuticals Inc.'s strategy and financial outlook.
Key Players & Entities
- Oramed Pharmaceuticals Inc. (company) — the registrant filing the 8-K
- January 17, 2024 (date) — date of the earliest event reported
- January 19, 2024 (date) — date the 8-K was filed
- 001-35813 (other) — Commission File Number
- ORMP (other) — Trading symbol for Common Stock
- The N (other) — Exchange on which Common Stock is registered (partial name)
FAQ
What was the specific item reported in Oramed Pharmaceuticals Inc.'s 8-K filing on January 19, 2024?
The 8-K filing reported on "Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers" as per the Item Information section.
When did the earliest event reported in this 8-K filing occur?
The earliest event reported in this 8-K filing occurred on January 17, 2024, as stated in the 'Date of report (Date of earliest event reported)' section.
What is the trading symbol for Oramed Pharmaceuticals Inc.'s Common Stock?
The trading symbol for Oramed Pharmaceuticals Inc.'s Common Stock is ORMP, as listed under 'Securities registered pursuant to Section 12(b) of the Act'.
What is Oramed Pharmaceuticals Inc.'s Commission File Number?
Oramed Pharmaceuticals Inc.'s Commission File Number is 001-35813, as indicated in the filing.
What is the business address of Oramed Pharmaceuticals Inc. as listed in the filing?
The business address of Oramed Pharmaceuticals Inc. is 1185 Avenue of the Americas, Third Floor, New York, New York 10036, according to the filing.
Filing Stats: 426 words · 2 min read · ~1 pages · Grade level 12.2 · Accepted 2024-01-19 16:45:09
Key Financial Figures
- $0.012 — ch registered Common Stock, par value $0.012 ORMP The Nasdaq Capital Market, Tel
Filing Documents
- ea191796-8k_oramed.htm (8-K) — 22KB
- 0001213900-24-004905.txt ( ) — 190KB
- ormp-20240117.xsd (EX-101.SCH) — 3KB
- ormp-20240117_lab.xml (EX-101.LAB) — 33KB
- ormp-20240117_pre.xml (EX-101.PRE) — 22KB
- ea191796-8k_oramed_htm.xml (XML) — 3KB
02. Departure of Directors or Certain Officers
Item 5.02. Departure of Directors or Certain Officers Election of Directors Appointment of Certain Officers Compensatory Arrangements of Certain Officers. On January 17, 2024, Mr. Yadin Rozov, a member of the Board of Directors (the "Board") of Oramed Pharmaceuticals Inc. (the "Company"), notified the Company of his intention to resign from the Board for personal reasons, effective immediately. Mr. Rozov did not advise the Company of any disagreement with the Company on any matter relating to its operations, policies or practices. 1
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. ORAMED PHARMACEUTICALS INC. By: /s/ Nadav Kidron Name: Nadav Kidron Title: President and CEO January 19, 2024 2